Midostaurin (PKC412)

For research use only. Not for use in humans.

目录号:S8064 别名: CGP 41251 中文名称:米哚妥林

Midostaurin (PKC412) Chemical Structure

CAS No. 120685-11-2

Midostaurin (pkc412, CGP 41251) 是一种多靶点激酶抑制剂,作用于PKCα/β/γSykFlk-1AktPKAc-Kitc-Fgrc-SrcFLT3PDFRβVEGFR1/2IC50为80-500 nM。

规格 价格 库存 购买数量  
RMB 902.37 现货
RMB 3011.99 现货
RMB 32678.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Midostaurin (PKC412)发表文献23篇:

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Midostaurin (pkc412, CGP 41251) 是一种多靶点激酶抑制剂,作用于PKCα/β/γSykFlk-1AktPKAc-Kitc-Fgrc-SrcFLT3PDFRβVEGFR1/2IC50为80-500 nM。
靶点
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
体外研究

Midostaurin(pkc412)是一种广谱的蛋白激酶抑制剂。Midostaurin(pkc412)强烈与常规PKC-α, -β 和 -γ, PDGFRβ, VEGF-R2, VEGF-R1,及CDK 1-cyclin B复合物的ATP结合位点相互作用。Midostaurin(pkc412)在相似的亚微摩尔浓度时,在体外抑制多种人类和动物细胞系的生长。Midostaurin(pkc412) 在体外也有效抑制胶质母细胞瘤增殖,且诱导细胞在G2/M期累积,并形成巨核,具有广泛的碎片和凋亡小体。Midostaurin(pkc412)在体外能够逆转肿瘤细胞中p-糖蛋白介导的多药耐药性。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= NFrIeG44OiCq MlrnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVA:OTJibl2= NFnmNGEyQTZ3NESwPC=>
RS4-11 cells NEPnVG5HfW6ldHnvckBie3OjeR?= M4\COFIhcA>? MoHMTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCUU{StNVEh[2WubIOgZYZ1\XJiMjDodpMh[nliZXzlZ5Rzd2OqZX3pcJVucW6nc3PlcoNmKGG|c3H5MEBKSzVyPUGzJI5O MoLrNVk3PTR2MEi=
CGTH-W-1 cell NF7mbHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Moq4TY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQzNjZ3IN88US=> NF7RUlBUSU6JRWK=
SW982 cell NWrmW2s6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYXyVWJ3UW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjV6IN88US=> NHTK[3hUSU6JRWK=
human EoL-1-cell cell NIjwXIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDqTY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTJwMEigcm0> NWXDe|RYW0GQR1XS
MOLM-13 cells MlrBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlXBO|IhcA>? M1\HWGlvcGmkaYTpc44hd2ZiRlzUN{BKXERiaHX0[ZJwgnmpb4XzJI12fGGwdDDpckBpfW2jbjDNU2xONTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhT0l3ME2wMlA2PSEQvF2= NHLyXYczPjB6MUCyNy=>
KASUMI-1 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkW5TY5pcWKrdHnvckBw\iCqdX3hckBMSVOXTVmtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODZyMU[g{txO MUnTRW5ITVJ?
NCI-H1755 cell MlS2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEHWO|ZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwME[yO|Mh|ryP NUi0OIVNW0GQR1XS
human MES-SA cell NEf6cY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlHmTY5pcWKrdHnvckBw\iCqdX3hckBOTVNvU1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA4PTR2IN88US=> M2\NOHNCVkeHUh?=
human HCC1395 cell M1jFUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXBPVVrUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOESyPEDPxE1? NX:5[3FDW0GQR1XS
human D-336MG cell M4fhTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PzV2IN88US=> M{X3S3NCVkeHUh?=
CHP-212 cell NFPrcHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MorrTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDd5MzFOwG0> MoDDV2FPT0WU
human KM12 cell MoLQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH:zU4NKdmirYnn0bY9vKG:oIHj1cYFvKEuPMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6Ojd3IN88US=> MYnTRW5ITVJ?
A204 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTqTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNFA2OiEQvF2= M4j2eHNCVkeHUh?=
CAL-51 cell M3PHUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVA4ODlizszN MWrTRW5ITVJ?
human A431 cell NEnG[JBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGHnfYJKdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjF4IN88US=> M1fKNHNCVkeHUh?=
NCI-H650 cell MkDMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIjve5JKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMUewPEDPxE1? MV\TRW5ITVJ?
A427 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrlTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVkyQCEQvF2= NHvXdHNUSU6JRWK=
human 769-P cell NHLFbY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MonhTY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVIxQDJizszN MornV2FPT0WU
SW1710 cell Mn7ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M325SWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOzNzNjFOwG0> NVzneWJlW0GQR1XS
human H4 cell NUjYNWx{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfCRXZzUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM6PjNizszN NG\6XoJUSU6JRWK=
HT-1080 cell NVLCdpdiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHK0RZNKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUiyJO69VQ>? NVTQWGFUW0GQR1XS
human PANC-03-27 cell MkLoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXP4c5dsUW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOlAzKM7:TR?= NULGWmVTW0GQR1XS
A375 cells NEHtUFdEgXSxdH;4bYNqfHliYYPzZZk> MlK2O|IhcA>? NVrmPJJHXG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEmFNUC9NE4yQCEQvF2= NEL5SGsyQTZ3NESwPC=>
human HOP-62 cell NVjUeWQ1TnWwY4Tpc44h[XO|YYm= NWTmSZM5UW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF6MEezJO69VQ>? NH3mdGhUSU6JRWK=
human U031 cell MmjMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5Olk5KM7:TR?= M3vLSnNCVkeHUh?=
mouse BAF3 cells NXjD[FhYWHKxbHnm[ZJifGmxbjDhd5NigQ>? NIOwfJpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgeJJidnOob4Lt[YQhf2m2aDDaUmYyQThvRlfGVlEh[2:wc4TyeYN1NCCLQ{WwQVAvOiEQvF2= MWKyNVk{PjV2Mh?=
human G-402 cell M{LkUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYXrbYRxUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB{NUOg{txO M3LVNnNCVkeHUh?=
human G-361 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFg2OyEQvF2= Mn;PV2FPT0WU
NCI-H810 cell NELlW5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkTMTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjFyMkeg{txO MlHSV2FPT0WU
NCI-H2030 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWXNSWhbUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKzNFA3KM7:TR?= Mn\WV2FPT0WU
human HCT-116 cell MlXOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PTZ6IN88US=> M1nYWHNCVkeHUh?=
human SNU-423 cell MmjQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXeyOZAyUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtOFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{[1O{DPxE1? M2XQ[XNCVkeHUh?=
human SCC-4 cell NX7qS2JVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHzCeWdKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzl4NzFOwG0> NHfzSXFUSU6JRWK=
human SW48 cell M3fyU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3;GO2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlY3QCEQvF2= NHjKTo5USU6JRWK=
human SF295 cell NF20ZVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn;mTY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlczPTdizszN M2XU[XNCVkeHUh?=
MDA-MB-231 cell Mn;rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUX3OINzUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yPFExOSEQvF2= NXrLWYtZW0GQR1XS
A172 cell NIjGNoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK5NVUh|ryP NHzGd2dUSU6JRWK=
human BCPAP cell M33lRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml72TY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlk5PzlizszN MYrTRW5ITVJ?
human COLO-792 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfxOXVKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{OUm3NkDPxE1? MX\TRW5ITVJ?
human DU-145 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUTIOlNlUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjNzOEi5JO69VQ>? NXfJT3FnW0GQR1XS
NCI-H2122 cell NH65W5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3XEU2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MkK4OUDPxE1? NG\CeY9USU6JRWK=
human SK-UT-1 cell NVHyWXBET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NW\pZpdvUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|Mkm1NkDPxE1? NIG4S5ZUSU6JRWK=
LXF-289 cell NETWdolIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzQTY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ojl4NTFOwG0> NYTOXWpbW0GQR1XS
human NCI-H1792 cell M1r1bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkHPTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MEm2JO69VQ>? MUTTRW5ITVJ?
MCF7 cell M3Xv[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVH0XnRZUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzJ5NDFOwG0> M13tRXNCVkeHUh?=
HCT-15 cell MnLXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHe4TnVKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2M{Kg{txO NX\QNFd2W0GQR1XS
human NCI-H358 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> Mo\FV2FPT0WU
human HLE cell NUHWbo0xT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3exT2lvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zN|c2OiEQvF2= NETL[FlUSU6JRWK=
human SW1088 cell NIXXSZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGDjSFhKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN5OUeg{txO M1;jenNCVkeHUh?=
human K5 cell NIDUVY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYrDT3VRUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|YyPDlizszN MlT5V2FPT0WU
human SR cell M{XleGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zae2lvcGmkaYTpc44hd2ZiaIXtZY4hW1JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2OVcyKM7:TR?= NWXicXFbW0GQR1XS
human Calu-3 cell Ml7QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y5OjVizszN NHfVUpZUSU6JRWK=
human SK-MEL-30 cell M1fybWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml7KTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7OUGzJO69VQ>? MUXTRW5ITVJ?
human SW780 cell NITQR|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHNYPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NVE1OiEQvF2= MnrwV2FPT0WU
NCI-H1563 cell NXTrXY1[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTZTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1OlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzNEi0JO69VQ>? NYjxUHdnW0GQR1XS
human MKN45 cell NFj4T3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJG1MVjR3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NVk{OSEQvF2= NUTXNYViW0GQR1XS
MDA-MB-157 cell NU\ac5VmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml73TY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkCxOUDPxE1? MmHmV2FPT0WU
human NCI-H522 cell NGHqboZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OjNizszN NFfyW3ZUSU6JRWK=
human A2780 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vrXmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4PTB|IN88US=> Moq4V2FPT0WU
human A498 cell NEXVdHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\sbFFvUW6qaXLpeIlwdiCxZjDoeY1idiCDNEm4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PzZ7MzFOwG0> NIXkcHVUSU6JRWK=
human BxPC-3 cell NH7mcGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojvTY5pcWKrdHnvckBw\iCqdX3hckBDgFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ6OzZ4IN88US=> Ml3MV2FPT0WU
human A2058 cell MnfBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HibmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzQDR2IN88US=> M1q3e3NCVkeHUh?=
human PC-14 cell MnrrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mmm4TY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVM5PTVizszN NXTMTZlvW0GQR1XS
human KG-1 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUG3WJM4UW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PTRzOTFOwG0> MWjTRW5ITVJ?
human A375 cell NES2N2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUXteJJ3UW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PjFyMzFOwG0> NWnONpFiW0GQR1XS
human SW1783 cell M1nid2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4fXdmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzN5IN88US=> MV7TRW5ITVJ?
human MKN1 cell MmnOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{Cz[GlvcGmkaYTpc44hd2ZiaIXtZY4hVUuQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFg1OTJizszN NXThU4ZqW0GQR1XS
NCI-H1650 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVLH[nVUUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4PVE364DCzszN MYnTRW5ITVJ?
human HT-1376 cell M3:zR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXi2elk3UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xN|c3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MkmxPEDPxE1? Ml;mV2FPT0WU
SW872 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{i1PGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1PDV7IN88US=> NYPzdo5wW0GQR1XS
human RT-112 cell NX\C[2pPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\jV3BKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTd2OEOg{txO MW\TRW5ITVJ?
human HT-29 cell M3W0PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHOTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVc6QTZizszN MVPTRW5ITVJ?
human U-266 cell Mnz1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1T1eWlvcGmkaYTpc44hd2ZiaIXtZY4hXS1{Nk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5OzB{IN88US=> M1TmN3NCVkeHUh?=
human HEL cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVrvNYNyUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PTF5IN88US=> NES4R|JUSU6JRWK=
human KU812 cell NXfzZVB2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoO0TY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVEyPjRizszN MVTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-TYR / p-STAT5 / STAT5 / p-S6 / S6 / p-MAPK / MAPK / p-AKT / AKT ; 

PubMed: 28881711     


Effect of midostaurin and PRT062607 on TEL-SYK phosphorylation and phosphorylation of downstream effectors following 2 hr of treatment. For the experiment analyzing effects of midostaurin and PRT062607 on phosphorylation of TEL-SYK, SYK immunoprecipitation was carried out prior to immunoblotting with a PTYR (4G10) antibody. Immunoblotting was performed for the experiment analyzing effects of midostaurin and PRT062607 on signaling molecules downstream of TEL-SYK. Relative densitometry readings for pMAPK/total MAPK (normalized to control lane) are as follows: 0 nM midostaurin=1.0, 10 nM midostaurin=0.93, 100 nM midostaurin=0.41, 1000 nM midostaurin=0.04, 0 nM PRT062607=1.0, 10 nM PRT062607=0.72, 100 nM PRT062607=0.37, 1000 nM PRT062607=0.07. 

PKCα / PKCβ1 / PKCβ2 / PKCγ / PKCη / p-PKC / p-Bad / Bad / p-Bcl2 / Bcl-2 / p-p65 / p65; 

PubMed: 30584254     


The indicated PKC isoforms were up-regulated in the resistant BL cells, leading to elevated levels of PKC phosphorylation and the activation of downstream anti-apoptotic proteins.

28881711 30584254
体内研究 Midostaurin(pkc412) 除了直接抑制肿瘤细胞增殖(通过作用于PKCs),还通过抑制肿瘤血管生成(通过作用于VEGF受体酪氨酸激酶)来抑制肿瘤的生长。Midostaurin(pkc412)与细胞毒性剂,包括Doxorubicin, Cyclophosphamide, Cisplatin 和 Gemcitabine协同作用,产生的抗血管生成作用可能有助于抗转移和广泛的抗肿瘤活性。Midostaurin(pkc412)口服给药,最大耐受剂量为300 mg/kg以上。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[2]
- 合并
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 小时
  • Method: 每孔加入5 mM WST-1和0.2 mM 1-甲氧基PMS,然后使用酶标仪在450nm处测量吸光度。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: Colo 205 结肠移植瘤
  • Dosages: 50 mg/kg, 200 mg/kg, 每天一次
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+45% PEG 300+ddH2O
4mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 570.64
化学式

C35H30N4O4

CAS号 120685-11-2
储存条件 粉状
溶于溶剂
别名 CGP 41251

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03951961 Not yet recruiting Drug: Midostaurin Acute Myeloid Leukemia Adult Sebastian Scholl PD Dr. med.|Ludwig-Maximilians - University of Munich|University of Jena May 1 2020 Phase 2
NCT04097470 Recruiting Drug: Decitabine|Drug: Midostaurin AML/MDS Stichting Hemato-Oncologie voor Volwassenen Nederland|Swiss Group for Clinical Cancer Research December 5 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PKC Signaling Pathway Map

相关PKC产品

Tags: 购买Midostaurin (PKC412) | Midostaurin (PKC412)供应商 | 采购Midostaurin (PKC412) | Midostaurin (PKC412)价格 | Midostaurin (PKC412)生产 | 订购Midostaurin (PKC412) | Midostaurin (PKC412)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID